Overview

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activat

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-30

Target enrollment:

Participant gender:

Summary

A study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers related to the efficacy of Plonmarlimab.

Phase:

PHASE3

Details

Lead Sponsor:

TJ Biopharma Co., Ltd.

Treatments:

plonmarlimab